Bolt Biotherapeutics, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

The submission of this form does not create an attorney-client relationship.

Investigation Details

Bolt announced in a press release on May 14, 2024, that the Company would “cease further development of trastuzumab imbotolimod (BDC-1001)”, Bolt’s lead asset, “and reduce workforce by approximately 50%”. Following Bolt’s announcement, multiple analysts downgraded the Company’s stock. Following this news, Bolt’s stock dropped over 18% on May 15, 2024.